Information Library
Results for: Consulting - Phase II/III
In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions. Search our library today.
- Sort by:
- Recently Added
- Title
-
Cancer Treatments and the Search for Value
White Paper — April 2, 2012
Cancer Treatment and the Search for Value In September 2011, The Economist Intelligence Unit surveyed 399 senior executives from the life sciences industry and payer -
Accelerating Success in Oncology
Brochure — March 9, 2012
New Demands to Demonstrate Value Require New Strategy Proof of efficacy is no longer enough to ensure success in oncology. As the cost and complexity -
Quintiles Forms New Biomarker Research and Development Company
Press Release — January 18, 2012 – Quintiles announced that it has invested in a new company formed to provide oncology consulting services and new cancer biomarkers, the key to scientific selection of the right drug for the right patient.
-
DIA US 2012
Event — Conference Date(s): June 24 - June 28, 2012
Location: Philadelphia, PA Pennsylvania Convention Center
Booth Number: 1401
-
Quintiles Names New Global Head of Clinical & Data Operations
Press Release — October 6, 2011 – Quintiles announced that Steven Skolsky has been appointed Global Head of its Clinical & Data Operations (CDO) unit.
-
A Focus on CNS
Brochure — July 1, 2011
Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process. -
Malaria Prevention in Sub-Saharan Africa
Case Study — June 24, 2011
This study enabled us to be involved in bringing a malaria vaccine to Africa which could substantially reduce an infant mortality rate that currently stands -
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
White Paper — June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
Biomarkers in Alzheimers Disease
Presentation — March 17, 2011
The Quintiles Innovation Unit shares their knowledge on the use of biomarkers in compound development in clinical trials. -
Population PK/PD - Modeling and Simulation Optimization Tools
Brochure — February 11, 2011
Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation, available from Quintiles, is now endorsed by the FDA as often being instrumental in drug approval and labeling.
